Financials

	2025 *	2026 *
Net sales	14.43M 12.17M 11.1M 10.59M 19.67M 1.31B 20.4M 129M 51.28M 631M 54.11M 53M 2.21B	9.62M 8.11M 7.4M 7.06M 13.11M 873M 13.6M 86M 34.18M 420M 36.07M 35.33M 1.48B
Net income	-62.48M -52.71M -48.08M -45.84M -85.16M -5.67B -88.35M -559M -222M -2.73B -234M -230M -9.59B	-90.35M -76.22M -69.53M -66.28M -123M -8.2B -128M -808M -321M -3.95B -339M -332M -13.87B
Net Debt	-218M -184M -168M -160M -297M -19.81B -309M -1.95B -776M -9.54B -818M -802M -33.49B	-279M -235M -214M -204M -380M -25.31B -394M -2.49B -991M -12.18B -1.05B -1.02B -42.78B

* Estimated data More financial data

Company Profile

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	31.57 $	+13.24%	1,362,233
12/02/26	27.88 $	-2.04%	553,988
11/02/26	28.46 $	-1.96%	1,261,461
10/02/26	29.03 $	+70.87%	15,984,311

Delayed Quote Nyse

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.57USD

Average target price

51.00USD

Spread / Average Target

+61.55%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nyse Other stock markets 21:00:02 13/02/2026 GMT			5-day change	1st Jan Change
31.57 ^USD	+13.24%		+82.38%	+84.40%

02-13	Evommune Inc on Feb 12, enters securities purchase agreement with investors	RE
02-13	Evommune to Raise $125 Million Via Private Placement	MT

Capitalization	995M 840M 766M 730M 1.36B 90.36B 1.41B 8.9B 3.54B 43.5B 3.73B 3.66B 153B	P/E ratio 2025 *	-7.93x	P/E ratio 2026 *	-12.9x
Enterprise value	777M 655M 598M 570M 1.06B 70.55B 1.1B 6.95B 2.76B 33.96B 2.91B 2.85B 119B	EV / Sales 2025 *	53.9x	EV / Sales 2026 *	74.5x
Free-Float	-	Yield 2025 *	-	Yield 2026 *	-

02-13	Evommune Inc on Feb 12, enters securities purchase agreement with investors	RE
02-13	Evommune to Raise $125 Million Via Private Placement	MT
02-11	Evommune, Inc. announced that it expects to receive $125.300499 million in funding	CI
02-10	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
02-10	Top Midday Gainers	MT
02-10	Sector Update: Health Care Stocks Mixed Tuesday Afternoon	MT
02-10	Evommune Says Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial; Shares Rise	MT
02-10	Evommune Says its Atopic Dermatitis Treatment Achieved 'Statistically Significant' Outcomes in Proof-of-Concept Trial	MT
02-10	Evommune, Inc. Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis	CI
01-22	Oppenheimer Initiates Coverage on Evommune With Outperform Rating, $42 Price Target	MT
01-08	Raymond James Initiates Coverage on Evommune With Strong Buy Rating, $40 Price Target	MT
01-06	HC Wainwright Initiates Evommune at Buy With $35 Price Target	MT
12-21	Evommune, Inc.(NYSE:EVMN) added to S&P TMI Index	CI

01-22	Oppenheimer Initiates Coverage on Evommune With Outperform Rating, $42 Price Target	MT
01-08	Raymond James Initiates Coverage on Evommune With Strong Buy Rating, $40 Price Target	MT
01-06	HC Wainwright Initiates Evommune at Buy With $35 Price Target	MT
12-01	William Blair Initiates Coverage on Evommune With Outperform Rating	MT
12-01	Evercore ISI Initiates Coverage on Evommune With Outperform Rating, $40 Price Target	MT

Evommune, Inc. Share Price

Equities

EVMN

US30054Y1073

Biotechnology & Medical Research

Valuation: Evommune, Inc.

Chart: Evommune, Inc.

Latest news: Evommune, Inc.

Analysts' recommendations: Evommune, Inc.

Press Releases: Evommune, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Evommune, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-13	Evommune Announces $125 Million Private Placement	BU
02-10	Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis	BU
12-11	Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update	BU
11-06	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading	PR
11-06	NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading	AQ

1 day	+13.24%
1 week	+82.38%
Current month	+74.42%
1 month	+61.07%
3 months	+72.51%
Current year	+84.40%

1 week	21.8	33.2
1 month	15.97	33.2
Current year	14.77	33.2
1 year	13.88	33.2
3 years	13.88	33.2
5 years	13.88	33.2
10 years	13.88	33.2

Manager	Title	Age	Since
Eugene Bauer CTO	Chief Tech/Sci/R&D Officer	83	31/03/2020
Luis Peña CEO	Chief Executive Officer	63	31/03/2020
Kyle Carver DFI	Director of Finance/CFO	39	28/02/2022

Director	Title	Age	Since
Luis Peña BRD	Director/Board Member	63	31/03/2020
Eugene Bauer BRD	Director/Board Member	83	31/03/2020
David Cohen BRD	Director/Board Member	61	30/04/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EVOMMUNE, INC.	+13.24%	+82.38%	-	-	995M
LONZA GROUP AG	+1.19%	+1.93%	-11.45%	-4.56%	47.61B
BEONE MEDICINES AG	-0.10%	-2.22%	+49.90%	+44.95%	38.3B
CELLTRION, INC.	-0.21%	+8.18%	+36.90%	+65.96%	36.11B
IQVIA HOLDINGS INC.	-1.13%	-10.96%	-13.70%	-26.47%	28.31B
REVOLUTION MEDICINES, INC.	-1.05%	-1.21%	+136.81%	+277.09%	18.62B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+7.58%	+14.65%	+31,531.21%	+4,130.93%	15.44B
EUROFINS SCIENTIFIC SE	-1.37%	-5.06%	+29.40%	-5.36%	13.71B
ASCENDIS PHARMA A/S	-0.82%	-2.62%	+50.14%	+93.14%	13.28B
IONIS PHARMACEUTICALS, INC.	-1.44%	-6.82%	+159.66%	+108.92%	13.06B
Average	+1.59%	+7.37%	+3,552.10%	+520.51%	22.54B
Weighted average by Cap.	+0.33%	-0.55%	+2,204.68%	+332.64%